Immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC 45662).
Weir
M R
MR
Department of Medicine, University of Maryland Hospital, Baltimore 21201.
Li
X W
XW
Gomolka
D
D
Peppler
R
R
O'Bryan-Tear
G
G
Moran
M
M
D000085:Acetates; D000527:Alprostadil / Q000031:analogs & derivatives* / Q000494:pharmacology; D001094:Arachidonate 5-Lipoxygenase / Q000494:pharmacology; D002470:Cell Survival / Q000187:drug effects; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007166:Immunosuppressive Agents; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000276:immunology; D016859:Lipoxygenase Inhibitors; D008213:Lymphocyte Activation / Q000187:drug effects; D010636:Phenols; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000085:Acetates; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D016859:Lipoxygenase Inhibitors; D010636:Phenols; D015375:Receptors, Interleukin-2; C066992:(2-((3,5-di-t-butyl-4-hydroxyphenyl)thio)-1-methylpropoxy)acetic acid; D001094:Arachidonate 5-Lipoxygenase; D000527:Alprostadil; C054594:enisoprost